ClinicalTrials.gg
RecruitingNCT07551635Updated Oct 26, 2026

SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

A Phase 2 interventional study of FHD-286 in Small Cell Lung Cancer, sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 631 studies in Small Cell Lung Carcinoma with a site in United States — 112 open to participants now, 183 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
430th of 552
20 · median 55
Started
2026
with 38 others
Phase 2
186 of 631
24 open now
Primary completion
2028-01
later than 99 of 182 live
Registered
620th of 631
by date

Among the 631 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 430th largest by planned enrollment of the 552 interventional ones that give a count, is one of 39 that started in 2026, is one of 186 in phase 2, reaches primary completion later than 99 of the 182 other live ones, and was the 620th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

112 of the 631 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 631 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. All participants will receive FHD-286 orally once daily in 21-day cycles. The primary objective is to assess the objective response rate of FHD-286 in this population.

The names of the study drug involved in this study is:

  • FHD-286 (a small-molecule SMARCA4/2 ATPase (BRG1 and BRM) inhibitor targeting the SWI/SNF chromatin remodeling complex (also known as the BAF complex)
Read the detailed description

This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with extensive-stage small cell lung cancer and documented POU2F3 expression, who have progressed after prior platinum-based therapy.

FHD-286 has not been approved by the FDA or any other regulatory authorities around the world for the treatment of POU2F3 expressing small cell lung cancer.

The study includes clinical examinations, medical history collection, performance status evaluation, vital signs and weight checks, tumor assessments by one or more of the following tools: Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, or Positron Emission Tomography (PET) scans, blood tests, pregnancy test for women of childbearing potential, Electrocardiogram (ECG), Echocardiogram (ECHO) test, tumor tissue sample, and biobanking.

It is expected that about 20 people will take part in this research study.

Foghorn Therapeutics, Inc. is supporting this research study by providing study drug and partial funding. FHD-286 has not been approved by the FDA or any other regulatory authorities around the world for the treatment of POU2F3 expressing small cell lung cancer.

It is expected that about 20 people will take part in this research study Foghorn Therapeutics, Inc. is supporting this research study by providing study drug and partial funding.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • POU2F3-Positive Small Cell Lung Cancer
  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult age l8 years or older, who have provided written .
  • or cytologically confirmed extensive stage SCLC with documented disease progression or recurrence after prior platinum-based therapy with or without .
  • Positive >50% POU2F3 expression by IHC staining.
  • Participants must have based on v1.1.
  • (ECOG) performance status of 0 or l.
  • Participants must meet the following organ and marrow function criteria:

    • leukocytes ≥2,000/mcL
    • (ANC) ≥1,000/mcL
    • ≥50,000/mcL
    • ≥9 g/dL
    • total ≤ 1.5 institutional (ULN); Unless considered due to advanced involvement or Gilbert syndrome, with PI approval
    • (SGOT)/ALT(SGPT) ≤3.0 × institutional ULN; Unless considered due to advanced malignancy involvement, with PI approval
    • ALP ≤3.0 × institutional ULN; Unless considered due to advanced malignancy involvement, with PI approval
    • ≤1.5 × institutional ULN or international normalized ratio (INR) ≤1.4
    • activated partial thromboplastin time (aPTT) ≤1.5 × institutional ULN; PI approval is required for a participant receiving anticoagulation therapy for treatment of a stable medical condition
    • creatinine ≤ 1.5 institutional ULN OR (GFR) ≥40 mL/min/1.73 m2
    • ≥40% by ECHO
    • no known portal vein thrombosis
    • adequate cardiovascular, respiratory, and immune system function, in the opinion of the investigator
  • Agree to abide by dietary and other considerations required during the study
  • The effects of FHD-286 on the developing human fetus are unknown. For this reason, women of (WOCBP) sexually active with male partners and fertile men sexually active with WOCBP must agree to use dual measures (hormonal or barrier method of birth control; abstinence; condom), beginning at the screening visit and until 90 days after taking the last dose of FHD-286. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Participants must agree to refrain from donating sperm/ova from the screening visit through 90 days after the last dose of FHD-286.
  • The potential risk to fertility posed by FHD-286 is unknown. It is recommended that subjects discuss options for fertility preservation with their doctor before starting treatment.
  • See Section 5.2.2 for a list of acceptable birth control methods. Information must be captured appropriately within the site's source documents.
  • Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
  • Note: Non-child-bearing potential is defined as follows:

    • >45 years of age and has not had menses for >1 year. Participants who have been amenorrhoeic for \<2 years without history of a hysterectomy or bilateral oophorectomy must have a follicle-stimulating hormone value in the range upon screening evaluation.
    • Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Must be willing and able to swallow pills

Exclusion criteria

Exclusion Criteria:

  • Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
  • Participants who are receiving any therapy
  • Symptomatic (untreated, asymptomatic brain metastases are eligible if size \<6 mm).
  • Participants receiving any medications or substances that are strong inhibitors, strong inducers, or sensitive substrates (with narrow therapeutic indices) of CYP3A enzymes are ineligible (see also Section 3.3).

    • Individuals must have stopped treatment with strong CYP3A inhibitors at least 1 week or 5 half-lives, whichever is longer, before the first dose of study drug. Strong CYP3A inhibitors may be permitted with PI approval; the FHD-286 dose should be reduced to 1.5 mg QD when a strong CYP3A inhibitor is in use.
    • Individuals must have stopped treatment with strong CYP3A inducers at least 2 weeks or 5 half-lives, whichever is longer, before the first dose of study drug. Strong CYP3A inducers may be permitted with PI approval.
    • Stable doses of that are sensitive CYP3A substrates with narrow therapeutic indices may be permitted with PI approval.
  • Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/ procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
  • Taking proton pump inhibitors (PPIs). Administration of PPIs must be stopped or switched to another acid-reducing agent within 7 days before study entry. If it is medically necessary to administer PPIs concomitantly with FHD-286, this may be permitted with PI approval.
  • Taking or increasing doses of systemic therapy or any other systemic immunosuppressive medication. The use of a stable dose of such therapies may be permitted with PI approval. Local/targeted therapies, eg, inhaled or topical steroids, are acceptable. Appropriate steroid replacement to manage endocrine toxicities resulting from prior systemic anticancer therapy is acceptable.
  • Currently pregnant. Female participants must have a negative urine pregnancy test within 7 days prior to taking study treatment if of .
  • Currently breastfeeding.
  • Planning to become pregnant within 1 year after start of study treatment.
  • Any active cancer requiring systemic treatment or prior cancer treated within past 2 years (excluding non-melanoma skin cancer, DCIS, low risk prostate cancer not requiring treatment, superficial bladder cancer, or other low risk cancers after communication with PI).
  • Timing requirements with respect to prior therapy and surgery:

    • Radiotherapy: At least 2 weeks must have elapsed since last radiotherapy
    • Surgery: Participant must be recovered from any clinically relevant effects of any prior surgery
  • Any active infection requiring treatment (excluding with undetectable viral load). Active (defined by presence of Hep B sAg) or C is not eligible, unless the individual has a sustained viral response to treatment or immunity to prior HBV infection.
  • Uncontrolled intercurrent illness that could limit or ability to complete study. This includes, but is not limited to:

    • >470 msec or other factors that increase the risk of QTc prolongation. Participants with QTcF >470 msec and bundle branch block and/or pacemaker rhythm may be enrolled with approval from PI.
    • class III/IV congestive heart failure of
    • Psychiatric illness/social situations that would limit compliance with study requirements
    • Any other prior or ongoing condition that, in the opinion of the investigator, could adversely affect the safety of the individual or impair the assessment of study results
  • GI dysfunction that would preclude adequate absorption, distribution, metabolism, or excretion of FHD-286
  • Known to any component of the FHD-286 formulation
  • Prior treatment with any SMARCA2/4 inhibitor, including FHD-286
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    FHD-286

    * Baseline visit * Cycle 1 through End of Treatment (21-day cycles) * Days 1 - 21: Predetermined dose of FHD-286 1X daily. Possible dose escalation or based on tolerability. * 30 day follow up post-treatment discontinuation * Annual follow up for up to 5 years.

    Drug: FHD-286

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is the percentage of participants achieving complete or partial response on treatment based on RECIST v1.1 criteria (Eisenhauer et al Eur J Ca 45:228-247, 2009).

    Time frame: Observed on treatment; Time frame is variable by patient as duration of treatment is event-driven per protocol section 5.5. Disease assessed on treatment every 2 cycles (cycle duration=21 days). Response follow-up expected up to 12 months.

Secondary outcomes

  1. Median Progression-Free Survival (PFS)

    PFS is defined as the time from start of treatment to time of disease progression (PD) or death from any cause, whichever occurs first. Participants alive without PD are censored at date of last disease evaluation (regardless of whether non-protocol therapy has been given). Median PFS is estimated based on the Kaplan-Meier method. PD is based on RECIST v1.1 criteria (Eisenhauer et al Eur J Ca 45:228-247, 2009).

    Time frame: Disease assessed on treatment every 2 cycles (cycle duration=21 days) and in long-term follow-up every 8 weeks until disease progression. Disease follow-up expected up to 5 years.

  2. Median Overall Survival

    OS is defined as the time from start of treatment until death due to any cause, or censored at the date last known alive. Median OS is estimated based on the Kaplan-Meier method.

    Time frame: Survival assessed up to 5 years.

  3. Median Time-To-Progression (TTP)

    TTP is defined as the time from start of treatment to disease progression (PD), or censored at date of last disease evaluation for those without PD reported. Median TTP is estimated based on the Kaplan-Meier method. PD is based on RECIST v1.1 criteria (Eisenhauer et al Eur J Ca 45:228-247, 2009).

    Time frame: Disease assessed on treatment every 2 cycles (cycle duration=21 days) and in long-term follow-up every 8 weeks until disease progression. Disease follow-up expected up to 5 years.

  4. Median Duration of Response (DOR)

    DOR is defined as the time from the documented objective response (partial or complete response) until disease progression (PD) or death, or censored at the time of their last disease evaluation. Median DOR is estimated based on the Kaplan-Meier method. Response and PD are based on RECIST v1.1 criteria (Eisenhauer et al Eur J Ca 45:228-247, 2009).

    Time frame: Disease assessed on treatment every 2 cycles (cycle duration=21 days) and in long-term follow-up every 8 weeks until disease progression. Disease follow-up expected up to 5 years.

  5. Treatment-Related Grade 3-4 Adverse Event (AE) Rate

    Percentage of participants who experience an AE of grade 3 or 4 with treatment attribution of possible, probable or definite per Common Toxicity Adverse Event Criteria (CTCAE) version 5 on treatment.

    Time frame: Observed on treatment plus 30 days; Time frame is variable by patient as duration of treatment is event-driven per protocol section 5.5. AEs assessed on treatment days 1, 8, and 15 during cycle 1 and day 1 of every cycle thereafter (cycle duration=21 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication.

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.

Of 150 non-industry phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 21 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Apr 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
Apr 27, 2026
StartActual
Apr 28, 2026was Sep 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
Dana-Farber Cancer Institute is now Recruiting
Oct 26, 2026
Start date
Sep 4, 2026→Apr 28, 2026 (actual)
Oct 26, 2026
Contact
Study contact changed: J•••@dfci.harvard.edu · •••6049→a•••@dfci.harvard.edu · •••6049; none listed→a•••@dfci.harvard.edu. See the current contact
Oct 26, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Dana-Farber Cancer Institute · Boston, United StatesContact J•••@dfci.harvard.edu · •••6049→a•••@dfci.harvard.edu · •••6049Contact person changed (no phone or email listed)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    Dana-Farber Cancer Institute is now Recruiting
    Start date Sep 4, 2026→Apr 28, 2026 (now actual)
    Contact Study contact changed: J•••@dfci.harvard.edu · •••6049→a•••@dfci.harvard.edu · •••6049; none listed→a•••@dfci.harvard.edu. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Dana-Farber Cancer Institute · Boston, United StatesContact J•••@dfci.harvard.edu · •••6049→a•••@dfci.harvard.edu · •••6049Contact person changed (no phone or email listed)
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07551635
Collaborators
Foghorn Therapeutics Inc.
Responsible party
Alissa Cooper (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Apr 27, 2026
Start date
Apr 28, 2026
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Alissa Cooper
Contact
alissa_cooper@dfci.harvard.edu
617-632-6049
Alissa Cooper
Contact
alissa_cooper@dfci.harvard.edu
Alissa Cooper
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camibirstat

Start the discussion